›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Breast Cancer Index®
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
HologicType:
Laboratory Developed Test
Related tests:
BCI is an RT-PCR assay on FFPE breast tumor tissue integrating two biomarkers: (1) HOXB13:IL17BR ratio (H/I) assessing endocrine responsiveness, and (2) Molecular Grade Index (MGI) from five proliferation genes. Evaluates 11 genes total (7 informational + 4 reference). Indicated for HR+, HER2-, LN- or LN+ (1-3 nodes) early-stage invasive breast cancer. Provides: quantitative late (post-5yr) and overall (0-10yr) distant recurrence risk, plus prediction of extended endocrine therapy benefit.
Cancer:
Breast Cancer
Gene:
BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B), CENPA (Centromere protein A), HOXB13 (Homeobox B13), IL17RB (Interleukin 17 Receptor B), NEK2 (NIMA Related Kinase 2), Other genes
See More ...
BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B), CENPA (Centromere protein A), HOXB13 (Homeobox B13), IL17RB (Interleukin 17 Receptor B), NEK2 (NIMA Related Kinase 2), Other genes, RACGAP1 (Rac GTPase activating protein 1), RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
Method:
RT-PCR
Confirmatory trial(s)
Confirmatory trial(s)